Dar es Salaam. Health practitioners in Tanzania are optimistic after the official registration of Lenacapavir, a long-acting ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales ...

Researchers from Brown University and the University of Rochester will lead a multi-institution project to test whether ...

A new study has overcome a long-standing challenge-how to isolate and study elusive HIV-infected cells called authentic reservoir clones (ARCs) that evade the immune system, making the disease ...

One-third of children with HIV who received very early ART had no detectable virus in their body for at least 12 weeks after stopping treatment, according to study findings. It was another sign that ...

A new study has overcome a long-standing challenge: how to isolate and study elusive HIV-infected cells called authentic reservoir clones (ARCs) that evade the immune system, making the disease ...

Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for ...

According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an ...

The 254 study participants with oropharyngeal cancer had a median age of 58, 95% were men, 52% were white, and 41% were Black ...

A new research paper was published in Volume 18 of Aging-US on February 8, 2026, titled "Single-cell transcriptomics reveal ...

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.

It has taken about two decades, but the world finally has a new, longer-acting injectable drug for HIV prevention. Yesterday, Kenya received 21,000 doses of Lenacapavir, also known as LEN, with about ...